Clinical Trial Update: Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study [Phase 2]

View source ↗

Summary

Phase 2 randomized study evaluating concurrent neoadjuvant chemoradiotherapy with trastuzumab for HER-2 positive gastroesophageal junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hebei Medical University | Conditions: Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN